Quisel John D, CEO, reported an open-market or private sale at Disc Medicine, Inc. involving 11112.000000 shares for an estimated $687477.22. Reported holdings after the transaction were 73965.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.29 to $62.27, inclusive. The Reporting Person undertakes to provi…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.31 to $62.58, inclusive.
The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date.
The shares underlying this option are fully vested and exercisable as of the date hereof.
0 other filings
0 recent txs